Risk, Progressive Licensing and the Health Benefits Lost by Over-Regulating New Drugs

Printer-friendly version

The purpose of this publication is to contribute to the public dialogue about drug safety regulation and to raise the awareness of the general public about some important but perhaps underappreciated concepts about risk that should be part of the decision-making process when drug-safety standards are defined.

More from this study

Subscribe to the Fraser Institute

Get the latest news from the Fraser Institute on the latest research studies, news and events.